Sulopenem
- Generic Name
- Sulopenem
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15NO5S3
- CAS Number
- 120788-07-0
- Unique Ingredient Identifier
- XX514BJ1XW
- Background
Sulopenem is under investigation in clinical trial NCT03357614 (Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults).
- Associated Conditions
- -
- Associated Therapies
- -
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Registration Number
- NCT04700787
- Locations
- 🇺🇸
Medical Facility, Saint Louis, Missouri, United States
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 1395
- Registration Number
- NCT03357614
- Locations
- 🇱🇻
Medical Facility, Valmiera, Latvia
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 674
- Registration Number
- NCT03358576
- Locations
- 🇵🇱
Medical Facility, Bielsk Podlaski, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath